Jisu Yum
Research Subjects
Jisu Yum has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hwa Pyoung Lee
InnoBation Bio, 189 Seongam-ro, Seoul 03929, Republic of Korea
1 shared publication - Jae Gwang Park
InnoBation Bio, 189 Seongam-ro, Seoul 03929, Republic of Korea
1 shared publication - Jae Youl Cho
Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea
1 shared publication - Jieun Oh
Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea
1 shared publication - Maro Yoo
Center for Liver and Pancreatobiliary Cancer, Hospital, National Cancer Center, Goyang 10408, Republic of Korea
1 shared publication - Minsu Kim
Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea
1 shared publication
Latest Publications
- Open Access
Acylcarnitines in Cancer Metabolism: Mechanistic Insights and Stratification Potential
Metabolic reprogramming constitutes a fundamental hallmark of malignancy, enabling cancer cells to sustain proliferation and survival under physiological stress. While aerobic glycolysis is well characterized, fatty acid oxidation (FAO) has emerged as a decisive driver of oncogenic progression and therapeutic resistance. Acylcarnitines (ACs), obligatory intermediates for the mitochondrial transport of long-chain fatty acids, have transcended their traditional categorization as passive metabolic byproducts to function as potent signaling entities and functional readouts of mitochondrial oxidative throughput. This review delineates the AC metabolic axis in oncology, examining the coordinated biochemical machinery, including the carnitine palmitoyltransferase (CPT) system, carnitine–acylcarnitine translocase (CACT; SLC25A20), and organic cation/carnitine transporter 2 (OCTN2), that governs cellular AC homeostasis. We further evaluate the clinical utility of altered AC profiles as non-invasive biomarkers for early diagnosis and risk stratification across diverse malignancies, highlighting their capacity to reflect metabolic bottlenecks and flux dynamics. Additionally, we scrutinize therapeutic strategies targeting the AC-FAO axis, demonstrating how the inhibition of key transporters and enzymes sensitizes tumors to conventional chemotherapy and immunotherapy. Ultimately, deciphering the systemic and spatial dynamics of ACs remains essential for advancing precision metabolic oncology and developing personalized therapeutic strategies based on metabolic profiling.
Open AccessAcylcarnitines in Cancer Metabolism: Mechanistic Insights and Stratification Potential
Metabolic reprogramming constitutes a fundamental hallmark of malignancy, enabling cancer cells to sustain proliferation and survival under physiological stress. While aerobic glycolysis is well characterized, fatty acid oxidation (FAO) has emerged as a decisive driver of oncogenic progression and therapeutic resistance. Acylcarnitines (ACs), obligatory intermediates for the mitochondrial transport of long-chain fatty acids, have transcended their traditional categorization as passive metabolic byproducts to function as potent signaling entities and functional readouts of mitochondrial oxidative throughput. This review delineates the AC metabolic axis in oncology, examining the coordinated biochemical machinery, including the carnitine palmitoyltransferase (CPT) system, carnitine–acylcarnitine translocase (CACT; SLC25A20), and organic cation/carnitine transporter 2 (OCTN2), that governs cellular AC homeostasis. We further evaluate the clinical utility of altered AC profiles as non-invasive biomarkers for early diagnosis and risk stratification across diverse malignancies, highlighting their capacity to reflect metabolic bottlenecks and flux dynamics. Additionally, we scrutinize therapeutic strategies targeting the AC-FAO axis, demonstrating how the inhibition of key transporters and enzymes sensitizes tumors to conventional chemotherapy and immunotherapy. Ultimately, deciphering the systemic and spatial dynamics of ACs remains essential for advancing precision metabolic oncology and developing personalized therapeutic strategies based on metabolic profiling.